Iodine replacement in fibrocystic disease of the breast
- PMID: 8221402
Iodine replacement in fibrocystic disease of the breast
Abstract
Objective: To determine the response of patients with fibrocystic breast disease to iodine replacement therapy.
Design: Review of three clinical studies beginning in 1975: an uncontrolled study with sodium iodide and protein-bound iodide; a prospective, control, crossover study from iodide to molecular iodine; and a prospective, control, double-blind study with molecular iodine.
Setting: University affiliated breast-treatment clinics.
Patients: Study 1: 233 volunteers received sodium iodide for 2 years and 588 received protein-bound iodide for 5 years. Study 2: the treatment of 145 patients from study 1 treated with protein-bound iodide for several months who still had symptoms was switched to molecular iodine 0.08 mg/kg; 108 volunteers were treated initially with molecular iodine. Study 3: 23 patients received molecular iodine, 0.07 to 0.09 mg/kg body weight; 33 received an aqueous mixture of brown vegetable dye and quinine. The numbers in study 2 increased over the review period so that 1365 volunteers were being treated with molecular iodine by 1989.
Interventions: All patients in study 3 had pre- and post-treatment mammography and measurement of serum triiodothyronine, thyroxine and thyroid-stimulating hormone levels.
Main outcome measures: Subjective evaluation--freedom from pain--and objective evaluation--resolution of fibrosis.
Results: Study 1: 70% of subjects treated with sodium iodide had clinical improvement in their breast disease, but the rate of side effects was high; 40% of patients treated with protein-bound iodide had clinical improvement. Study 2: 74% of patients in the crossover series had clinical improvement, and objective improvement was noted in 72% of those who received molecular iodine initially. Study 3: in the treatment group 65% had subjective and objective improvement; in the control group there was a subjective placebo effect in 33% and an objective deterioration of 3%.
Conclusions: The fibrocystic breast reacts differently to sodium iodide, protein-bound iodide and molecular iodine. Molecular iodine is nonthyrotropic and was the most beneficial.
Comment in
-
Elemental iodine: relief for the painful breast?Can J Surg. 1993 Oct;36(5):405. Can J Surg. 1993. PMID: 8221395 No abstract available.
Similar articles
-
Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.Laryngoscope. 2007 Jan;117(1):3-15. doi: 10.1097/01.mlg.0000245058.11866.15. Laryngoscope. 2007. PMID: 17202923 Review.
-
Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.Clin Endocrinol (Oxf). 2006 Jun;64(6):617-24. doi: 10.1111/j.1365-2265.2006.02515.x. Clin Endocrinol (Oxf). 2006. PMID: 16712662
-
Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.Arch Neurol. 2006 May;63(5):729-35. doi: 10.1001/archneur.63.5.729. Arch Neurol. 2006. PMID: 16682542 Clinical Trial.
-
[Effect of iodine and thyroid hormones in the induction and therapy of Hashimoto's thyroiditis].Nuklearmedizin. 1999;38(5):144-9. Nuklearmedizin. 1999. PMID: 10488481 Clinical Trial. German.
-
[Breast dysplasia. Review of the drugs used in its treatment].Rev Paul Med. 1986 Mar-Apr;104(2):82-6. Rev Paul Med. 1986. PMID: 3544146 Review. Portuguese. No abstract available.
Cited by
-
Self-Assembling Imageable Silk Hydrogels for the Focal Treatment of Osteosarcoma.Front Cell Dev Biol. 2022 Jun 20;10:698282. doi: 10.3389/fcell.2022.698282. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35794868 Free PMC article.
-
The Impact of Iodine Concentration Disorders on Health and Cancer.Nutrients. 2022 May 26;14(11):2209. doi: 10.3390/nu14112209. Nutrients. 2022. PMID: 35684009 Free PMC article. Review.
-
Molecular Iodine Has Extrathyroidal Effects as an Antioxidant, Differentiator, and Immunomodulator.Int J Mol Sci. 2021 Jan 27;22(3):1228. doi: 10.3390/ijms22031228. Int J Mol Sci. 2021. PMID: 33513754 Free PMC article. Review.
-
Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study.Nutrients. 2019 Jul 17;11(7):1623. doi: 10.3390/nu11071623. Nutrients. 2019. PMID: 31319484 Free PMC article. Clinical Trial.
-
Thyroid function in the etiology of fatigue in breast cancer.Oncotarget. 2018 May 22;9(39):25723-25737. doi: 10.18632/oncotarget.25438. eCollection 2018 May 22. Oncotarget. 2018. PMID: 29876020 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources